ArticleJournal of viral hepatitis2026
A New Nomogram for Mortality Prediction Within 5 Years in Portal Vein Thrombosis due to Hepatitis B-Related Cirrhosis.
Article in Journal of viral hepatitis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to develop a nomogram model intended for predicting long-term mortality in patients suffering from hepatitis B-related cirrhosis associated with Portal vein thrombosis (PVT). A total of 961 patients were recruited from January 2015 to December 2023, forming the training cohort. We analysed independent risk factors affecting 5-year mortality through COX regression, from which we constructed a nomogram. To assess the nomogram's utility, we employed the receiver operating characteristic (ROC) curve, C-index, calibration curves, and decision curve analysis (DCA). The independent prognostic factors retained in the final model for patients with hepatitis B-related cirrhosis complicated by PVT included age (HR = 1.09, 95% CI: 1.06-1.11; p < 0.001), leukocyte count (WBC) (HR = 1.09, 95% CI: 1.03-1.17; p = 0.002), and the neutrophil-to-lymphocyte ratio (NLR) (HR = 1.29, 95% CI: 1.22-1.35; p < 0.001), along with serum sodium (HR = 0.94, 95% CI: 0.90-0.98; p = 0.005). The AUROC values for the nomogram were 0.906 (95% CI: 0.891-0.921) in the training cohort and 0.910 (95% CI: 0.885-0.927) in the validation cohort, demonstrating improved performance and discriminatory ability compared to current models, including CTP and MELD scores. Age, leukocyte count (WBC), NLR, and serum sodium emerged as independent risk factors impacting prognosis for patients with hepatitis B cirrhosis and PVT within 5 years. The nomogram developed in this research holds significant potential for accurately predicting the outcomes of these patients within 5 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.